Literature DB >> 1480509

Effects of pituitary adenylate cyclase activating polypeptide (PACAP) and vasoactive intestinal polypeptide (VIP) on the cardiovascular system in sheep.

K Sawangjaroen1, C R Dallemagne, R B Cross, J D Curlewis.   

Abstract

The cardiovascular effects of PACAP and VIP were studied in intact conscious sheep; PACAP (0.008, 0.04, 0.2, and 1.0 nmol/min) and VIP (0.07, 0.2, 0.6, and 1.8 nmol/min) were infused in conscious sheep for periods of 10 min. For each peptide there was a dose-dependent increase in heart rate. At the highest doses tested, pulse pressure and mean arterial pressure tended to increase and decrease, respectively. However, only the decrease in mean arterial pressure following the highest dose of VIP reached significance. At the highest doses tested, heart rate increased nearly threefold during the infusion while mean arterial pressure declined by 18.5%. In individual animals the decrease in blood pressure and increase in heart rate occurred simultaneously, so that we were unable to conclude whether the increase in heart rate was due to a baroreceptor reflex.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1480509     DOI: 10.1016/0196-9781(92)90068-e

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  3 in total

1.  Pituitary adenylate cyclase activating peptides relax human pulmonary arteries by opening of KATP and KCa channels.

Authors:  L Bruch; S Rubel; A Kästner; K Gellert; M Gollasch; C Witt
Journal:  Thorax       Date:  1998-07       Impact factor: 9.139

2.  PACAP induces bradycardia in guinea-pig heart by stimulation of atrial cholinergic neurones.

Authors:  J Seebeck; W E Schmidt; H Kilbinger; J Neumann; N Zimmermann; S Herzig
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-10       Impact factor: 3.000

Review 3.  Inhibitory effect of PACAP on caspase activity in neuronal apoptosis: a better understanding towards therapeutic applications in neurodegenerative diseases.

Authors:  Agnieszka Dejda; Valérie Jolivel; Steve Bourgault; Tommy Seaborn; Alain Fournier; Hubert Vaudry; David Vaudry
Journal:  J Mol Neurosci       Date:  2008-05-28       Impact factor: 3.444

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.